

# The Power of Debate

Debates hold transformative power in the field of rheumatology and autoimmunity, offering an unparalleled platform to challenge established norms and ignite forward-thinking ideas. At CORA 2025, attendees can dive into 21 dynamic debates, each designed to address some of the most pivotal and thought-provoking issues in rheumatology today. This unique format brings together leading experts to argue opposing views on urgent clinical, diagnostic, and therapeutic questions. The debates stimulate critical thinking, inspire innovative approaches, and ultimately push the field towards more effective patient-centered solutions.

[Join CORA 2025](#)

## What Should We Use As the First-Line Treatment for RA?

### Debate 1

**Zoltan Szekanecz (Hungary)**  
b/tsDMARDs

**Andrea Rubbert-Roth (Switzerland)**  
MTX

## Are the New Classification Criteria a Step Forward in the Management of Antiphospholipid Syndrome?

### Debate 2

**Savino Sciascia (Italy)**

Yes

Jaume Alijotas-Reig (Spain)

No

## **LN Treatment: Early Combination vs. Standard Treatment**

### **Debate 3**

Ioannis Parodis (Sweden)

Early Combination

Laurent Arnaud (France)

Standard Treatment

## **The Use of Medical Cannabis in Rheumatic Pain Management: Valid Option or Unproven Treatment?**

### **Debate 4**

Howard Amital (Israel)

Valid Option

Winfried Häuser (Germany)

Unproven Treatment

## **Beyond Physical Examination – How to Approach to RA Management: Joint**

# Ultrasound or Synovial Biopsy?

## Debate 5

Maria-Antonietta D'Agostino (Italy)

Joint Ultrasound

Felice Rivellese (United Kingdom)

Synovial Biopsy

# Mepolizumab in EGPA: Does One Size Fit All?

## Debate 6

Benjamin Terrier (France)

Yes

Giacomo Emmi (Italy)

No

# TNFi or IL17i for the Slowing the Radiographic Progression in Spondyloarthritis?

## Debate 7

Mikkel Østergaard (Denmark)

TNFi

Salvatore D'Angelo (Italy)

IL17i

# **Gut Microbiome in Rheumatic Diseases: Revolutionary or Fake News?**

## **Debate 8**

**Francesco Ciccia (Italy)**  
**Revolutionary**

**Zoltan Szekanecz (Hungary)**  
**Fake News**

# **CAR-T Cells in Rheumatic Diseases: Game-Changer or Just a Buzz?**

## **Debate 9**

**Laura Bucci (Germany)**  
**Game-Changer**

**Marit Stockfelt (Sweden)**  
**Just a Buzz**

# **Is Seronegative Sjogren Syndrome a Distinct Clinical Entity? & Should Hydroxychloroquine Be Used in Patients With Sjogren Syndrome?**

## **Debate 10**

**Roberto Gerli (Italy)**  
**Yes**

Athanasios Tzioufas (Greece)

No

## **Early Biologic Treatment in Systemic Lupus: Necessary or Overemphasized?**

### **Debate 11**

Mariele Gatto (Italy)

Necessary

Chris Wincup (UK)

Overemphasized

## **Is Hematopoietic Stem Cell Transplantation (Really) a Valid Option for Patients with Systemic Sclerosis?**

### **Debate 12**

Dominique Farge (France)

Yes

Oliver Distler (Switzerland)

No

## **Can We Give Targeted Therapies in**

# **Patients With Cancer?**

## **Debate 13**

**Eden Sebbag (France)**

**Yes**

**Zoltan Szekanecz (Hungary)**

**No**

# **Are IPAF and UCTD Two Clinical Variants of the Same Systemic Autoimmune Disorder?**

## **Debate 14**

**Marco Sebastiani (Italy)**

**Two Clinical Variants**

**Szilvia Szamosi (Hungary)**

**The Same**

# **Do JAK Inhibitors Aggravate Comorbidities Such As Cardiovascular Disease and Cancer?**

## **Debate 15**

**Serena Bugatti (Italy)**

**Yes**

**Ernest Choy (UK)**

**No**

# **Should We Treat preRA/at Risk RA Individuals or Not?**

## **Debate 16**

**Andrew Cope (UK)**

**Yes**

**György Nagy (Hungary)**

**No**

# **Is It Common To Achieve the T2T goals in SLE Patients?**

## **Debate 17**

**Marta Mosca (Italy)**

**Yes**

**Anisur A. Rahman (UK)**

**No**

# **Axial Psoriatic Arthritis and axSpA: To Lump or to Split**

## **Debate 18**

**Phillip Sewerin (Germany)**

**To Lump**

**Ennio Lubrano (Italy)**

**To Split**

# **Should Immunosuppressive Drugs be Used in All Patients With the Limited Cutaneous Form of SSc?**

## **Debate 19**

**Marco Matucci-Cerinic (Italy)**

**Yes**

**Yannick Allanore (France)**

**No**

# **Is It Safe to Use Low-Dose Glucocorticoids in GCA?**

## **Debate 20**

**Francesco Muratore (Italy)**

**Yes**

**Peter Villiger (Switzerland)**

**No**

# **Transition from Psoriasis to Psoriatic Arthritis: Are We getting Closer?**

## **Debate 21**

**Alen Zabotti (Italy)**

**Yes**

**Dennis McGonagle (UK)**



No